Clinical trials: Fallopian Tubes Cancer
Fallopian Tube Cancer, Ovarian Cancer
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00838656
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 4 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- Warwick Medical School
Carcinoma of the Ovary, Fallopian Tube Cancer
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA…
- Conditions
- Carcinoma of the Ovary, Fallopian Tube Cancer, Peritoneal Serous-type Advanced Stage
- Trial name
- miRSa (NCT01391351)
- Testing
- blood samples
- Where
- 7 sites in France
- Volunteers
- 107 people
- Sponsor
- Centre Francois Baclesse
Metastatic Ovarian Carcinoma, Peritoneal Carcinomatosis
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer
Women with history of tumor response insufficient to allow complete cytoreductive surgery after three cycles of previous neoadjuvant systemic carboplatin-paclitaxel chemotherapy will be prospectively recruited in this trial.
- Conditions
- Metastatic Ovarian Carcinoma, Peritoneal Carcinomatosis, Stage III Ovarian Cancer, Stage III Fallopian Tube Cancer
- Trial name
- PIPACOVA (NCT04811703)
- Testing
- Combined PIPAC / IV chemotherapy treatment
- Where
- 6 sites in France
- Volunteers
- 15 people
- Sponsor
- Hospices Civils de Lyon
Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
This is a Phase 1b/2, open-label, 2-part, global study designed to investigate the anti-tumor activity as well as the safety and efficacy of BAT8006 in subjects with platinum resistance ovarian cancer
- Conditions
- Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06545617
- Testing
- BAT8006 for Injection
- Sponsor
- Bio-Thera Solutions
Ovarian Cancer, Epithelial Cancer
The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
The PROOV study is an open-label, monocenter, single-arm, prospective phase I/II trial with a safety lead-in, evaluating the feasibility of combining PARPi with HIPEC in stage III EOC patients.
- Conditions
- Ovarian Cancer, Epithelial Cancer, Fallopian Tube Cancer
- Trial name
- PROOV (NCT07460180)
- Testing
- Olaparib
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- The Netherlands Cancer Institute
Fallopian Tube Carcinoma, Ovarian Carcinoma
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This research trial studies biomarkers in patients with previously untreated invasive ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01295489
- Testing
- Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Peritoneal Neoplasms
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Background: Birinapant is an experimental cancer treatment drug. It removes certain proteins in cells, which helps to kill the cells.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01681368
- Testing
- Birinapant (TL32711)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) is the leading cause of gynecological malignancy-related deaths worldwide and is a substantial health threat to women.
- Conditions
- Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- Trientine (NCT03480750)
- Testing
- trientine dihydrochloride, pegylated liposomal doxorubicin, carboplatin
- Volunteers
- 18 people
- Sponsor
- National Cheng-Kung University Hospital
Epithelial Ovarian Cancer, Peritoneal Cancer
Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT
The purpose of this study is to determine, whether there is clinical benefit of using fdg-PET/CT (F-18-fluorodeoxyglucose- positron emission tomography/computed tomography)compared to contrast-enhanced CT in primary treatment of…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- Mupet (NCT01276574)
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Turku University Hospital